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Abstract
Background: Apolipoprotein E (ApoE), a cholesterol carrier associated with atherosclerosis, is a major risk factor for
Alzheimer’s disease (AD). The low-density lipoprotein receptor (LDLR) regulates ApoE levels in the periphery and in the
central nervous system. LDLR has been identified on astrocytes and a number of studies show that it modulates amyloid
deposition in AD transgenic mice. However these findings are controversial on whether LDLR deletion is beneficial or
detrimental on the AD-like phenotype of the transgenic mice.
Methodology/Principal Findings: To investigate the role of LDLR in the development of the amyloid related phenotype we
used an APP/PS1 transgenic mouse (5XFAD) that develops an AD-like pathology with amyloid plaques, astrocytosis and
microgliosis. We found that 4 months old 5XFAD transgenic mice on the LDLR deficient background (LDLR-/-) have
increased amyloid plaque deposition. This increase is associated with a significant decrease in astrocytosis and microgliosis
in the 5XFAD/LDLR-/- mice. To further elucidate the role of LDLR in relation with ApoE we have generated 5XFAD transgenic
mice on the ApoE deficient (ApoE-/-) or the ApoE/LDLR double deficient background (ApoE-/-/LDLR -/-). We have found that
ApoE deletion in the 4 months old 5XFAD/ApoE-/- mice decreases amyloid plaque formation as expected, but has no effect
on astrocytosis or microgliosis. By comparison 5XFAD/ApoE-/-LDLR -/- double deficient mice of the same age have increased
amyloid deposition with decreased astrocytosis and microgliosis.
Conclusions: Our analysis shows that LDL deficiency regulates astrocytosis and microgliosis in an AD mouse model. This
effect is independent of ApoE, as both 5XFAD/LDLR -/- and 5XFAD/ApoE-/- LDLR -/- mice show reduction in inflammatory
response and increase in amyloid deposition compared to control mice. These results demonstrate that LDLR regulates glial
response in this mouse model independently of ApoE and modifies amyloid deposition.
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Introduction
Alzheimer’s disease (AD), the major form of dementia, is an
age-related neurodegenerative disease that impairs basic cogni-
tive functions, primarily memory. AD is characterized by age-
dependant deposition of amyloid plaques and neurofibrillary
tangles [1]. Apolipoprotein (ApoE) is the major susceptibility gene
for the common late-onset form of Alzheimer’s disease and the
presence of the e4 allele increases the risk of developing AD [2].
Accumulating evidence suggests that the differential effects of
ApoE isoforms on Ab aggregation and clearance play a major role
in AD pathogenesis [3]. ApoE, a cholesterol carrier, is primarily
synthesized in the liver and the central nervous system (CNS) [4].
ApoE within the CNS is synthesized by astrocytes and microglia
[4]. Studies using huAPP transgenic mice that develop an AD-like
phenotype have shown that ApoE deletion exerts a beneficial
effect on Ab-fibrillogenesis and amyloid plaque formation in the
mouse brain without altering Ab-production. APP transgenic mice
deficient for ApoE show a dramatic decrease in fibrillary amyloid
deposits [5,6,7,8,9]. ApoE binds to a number of membrane
receptors, known as the low density lipoprotein receptor (LDLR)
family. Many of these structurally related proteins, including the
LDLR and the LDL receptor-related protein 1 (LRP1), have been
shown to have diverse roles ranging from cholesterol homeostasis
to nervous system development [10]. LDLR, the ancestor gene
of the group, has been originally identified as a receptor for
cholesterol-rich lipoproteins that regulates LDL-cholesterol me-
tabolism [11]. LDLR deficiency in humans causes familial hyper-
cholesterolemia (type IIA) [12] and inactivation of the LDLR gene
in the mouse increases cholesterol levels and causes atherosclerosis
[13].
Accumulating evidence suggests that cholesterol and cholesterol
related proteins are involved in the pathogenesis of AD in humans
and AD mouse models [14]. Although the LDLR has been shown
to have a major role in cholesterol and ApoE homeostasis in the
periphery [15,16] its role in the CNS remains unclear [17]. Some
LDLR polymorphisms showed a sex-dependent increased risk for
developing AD in humans [18,19]. In LDLR deficient mice, lack
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of LDLR increases brain ApoE but has no effect on hippocampal
or CSF cholesterol [20]. A number of studies using AD mice have
provided evidence that the family of proteins involved in
cholesterol metabolism as the ABCA1, the ApoA1, the SR-BI
and the LDLR are involved in the pathogenesis of the AD-like
phenotype in the mouse brain [21,22,23,24]. Previous studies
using different AD mouse models that were LDLR deficient
resulted in conflicting data on the effect of LDLR deficiency on the
amyloid related phenotype of the mice [20,25]. Lack of LDLR had
no effect on amyloid deposition in the brain in a study using a
huAPP transgenic mouse [20] while an analogous study using
another huAPP transgenic mouse showed a significant increase in
amyloid deposition [25]. A recent study where LDLR was over-
expressed in the brains of APP transgenic mice resulted in a
significant decrease of amyloid plaque formation, thus establishing
an important role for LDLR in the amyloid related pathology in
the mouse brain [26].
The focus of the present study was to elucidate the role of
LDLR deficiency in the amyloid-related phenotype in an AD
mouse model, as results from previous studies were conflicting, and
to examine to what extent the effect on amyloid deposition caused
by LDLR is exclusively mediated by ApoE. We used a transgenic
mouse (5XFAD) that expresses huAPP and huPS1 mutant
transgenes and develops an amyloid related pathology. Amyloid
deposits first appear in the subiculum and spread to the hippo-
campus and the cortex. We found that 4 months old 5XFAD/
ApoE-/- mice develop considerably less amyloid deposits, mainly
located to the subiculum, compared to 5XFAD mice. We gen-
erated 5XFAD/LDLR-/-, 5XFAD/ApoE-/- and 5XFAD/ApoE-/-
LDLR-/- double knock-out mice to evaluate the effect of the
LDLR deficiency in the amyloid plaque formation on the ApoE+/+
and the ApoE-/- background. Thioflavine-S positive amyloid
deposition was increased in the 5XFAD/LDLR-/- mice compared
to the 5XFAD control mice as well as in the 5XFAD/ApoE-/-
LDLR-/- compared to the 5XFAD/ApoE-/- mice. A significant
decrease both in the astrocytic and microglial response was
observed together with the increase in amyloid deposition in both
the 5XFAD/LDLR-/- and 5XFAD/ApoE-/-LDLR-/- mice. These
results demonstrate that the LDLR deficiency reduces the glial
response in the 5XFAD mice and this effect is independent of
ApoE.
Results
LDLR deficiency increases amyloid plaque formation
both in the 5XFAD/LDLR-/- and the 5XFAD/ApoE-/-
LDLR-/- transgenic mice
To elucidate the effect of LDLR deficiency on the AD-like
phenotype we used 4 months old female 5XFAD transgenic mice
as male 5XFAD mice of the same age displayed a significant delay
in the development of the amyloid pathology. A similar sex-
specific effect on amyloid deposition has been reported on other
AD mice [27]. Our analysis showed that 5XFAD/LDLR-/- mice
showed a significant increase in Thioflavine-S positive amyloid
deposits compared to the 5XFAD mice both in the hippocampus
(Fig. 1B upper photos) and the cortex (Fig. 1A upper photos)
(n = 7). Deletion of ApoE greatly reduced Thioflavine-S positive
amyloid plaque formation in 5XFAD/ApoE-/- transgenic mice,
with amyloid plaques restricted mainly at the subiculum (Fig. 1A
and B lower photos). 5XFAD/ApoE-/-LDLR-/- double knock-out
mice displayed a significant increase in amyloid plaque deposition,
compared to the 5XFAD/ApoE-/- mice in the hippocampus
(Fig. 1C) (n = 527). Quantification of the Thioflavine-S positive
amyloid plaque load in the hippocampus and the cortex in these
mice confirmed a significant increase in the absence of LDLR both
in the presence and in the absence of ApoE (Fig. 1D). These data
confirm that the absence of LDLR in the 5XFAD mouse model
results in the increase of the amyloid plaque formation
independently of ApoE.
LDLR deficiency increases ApoE in the brains of the
5XFAD/LDLR-/- mice and has no effect on APP processing
To confirm the effect of LDLR deficiency on ApoE levels in the
brains of the 5XFAD/LDLR-/- and 5XFAD control mice we
extracted and immunoblotted the plaque-associated fraction from
brain homogenates of the 5XFAD and 5XFAD/LDL-/- mice
(Fig. 2A). We found a significant increase in the brain levels of
ApoE in the 5XFAD/LDLR -/- mice compared to the 5XFAD
mice (Fig. 2B), as it has been previously reported [20,25].
To evaluate the effect of LDLR deletion on APP processing, we
analyzed protein extracts from mouse brains. Western- blot
analysis of total brain protein extracts for the full-length APP
and its proteolytic fragments (a- and b-CTFs) did not detect any
differences among the different genotypes (Fig. 2C). These data
support that the LDLR deletion has no effect on the levels of APP
or CTFs in the brains of the 5XFAD transgenic mice.
LDLR deficiency increases Ab deposition in the
hippocampus of the 5XFAD/LDLR-/- and the 5XFAD/
ApoE-/-LDLR-/-mice
Consistent with the increase in the Thioflavine-S positive amy-
loid deposits, 5XFAD/LDLR-/- and 5XFAD/ApoE-/-LDLR-/-
transgenic mice displayed increased Ab deposition detected by
6E10 antibody. Mouse brains of 4 months old 5XFAD/LDLR-/-
mice had increased total Ab immunoreactivity in the hippocampus
and the cortex compared to 5XFAD control mice (Fig. 3A upper
photos) (n = 7). This increase was statistically significant only in the
hippocampus and not in the cortex (Fig. 3B). The pattern of Ab-
deposition in the 5XFAD and the 5XFAD/LDLR-/- mice was
similar with more intense deposition in the subiculum and in the
molecular layer of the dentate gyrus of the hippocampus. A
significant increase in Ab immunoreactivity was also noticed in the
hippocampus of the 5XFAD/ApoE-/-LDLR-/- mice compared to
the 5XFAD/ApoE-/- mice (n = 527) (Fig. 3A lower photos and 3B
left graph). Also the pattern of Ab-deposition was similar with a
characteristic lack of deposition in the molecular layer of the
dentate gyrus of the hippocampus both in the 5XFAD/ApoE-/-
and the 5XFAD/ApoE-/-LDLR-/- mice. Comparison of Ab-
deposition in the cortices of the 5XFAD/ApoE-/- and the
5XFAD/ApoE-/-LDLR-/- mice showed a non significant increase
in the 5XFAD/ApoE-/- brains (Fig. 3B right graph). This could be
explained by the different pattern of Ab deposits between the two
genotypes in the cortex. 5XFAD/ApoE-/- mice developed a more
‘diffuse’ pattern covering a larger area, compared to the 5XFAD/
ApoE-/-LDLR-/- mice that showed a more ‘compact’ pattern
covering a smaller area (Fig. 3A lower photos).
Analysis of Ab40 and Ab42 levels by ELISA between 5XFAD
and 5XFAD/LDLR-/- mice showed an increase both in the
guanidine and lysis fractions in the 5XFAD/LDLR-/- brains,
reflecting the increase in Thioflavine-S deposition observed
in the 5XFAD/LDLR-/- mice. The same analysis between
the 5XFAD/ApoE-/- and the 5XFAD/ApoE-/-LDLR-/- mice
showed an increase in both Ab40 and Ab42 levels in the
guanidine extract.
This increase of Ab40 and Ab42 levels observed mainly in the
guanidine fraction suggests that LDLR deficiency promotes
fibrillar Ab formation (Fig. 3C.)
Increase of Ab Deposition by LDLR Deletion
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5XFAD/LDLR-/- and 5XFAD/ApoE-/-LDLR-/- transgenic mice
display decreased astrocytic and microglial response
5XFAD mice have been shown to have extended neuroin-
flammatory responses displaying a significant increase in astrocytic
and microglial response that is associated with age and amyloid
deposition [28]. To evaluate the effect of LDLR deficiency on the
glial response, astrocytic and microglial, we analysed female 4
month old 5XFAD and 5XFAD/LDLR-/- mice as well as
5XFAD/ApoE-/- and 5XFAD/ ApoE-/-LDLR-/- mice. Despite
the increase in the amyloid deposition that was expected to further
increase the glial response, in the 5XFAD/LDLR-/- mice GFAP
(astrocytic) and Iba-1 (microglial) staining was reduced compared
to 5XFAD littermates of the same gender and age. A similar effect
was exerted in the 5XFAD/ApoE-/-LDLR-/- mice where astro-
cytic and microglial response was reduced compared to the
5XFAD/ApoE-/- (Figs. 4A,B,C and 5A,B,C). This decrease of
GFAP and Iba1 staining was localized in the subiculum of the
hippocampus (Figs. 4A and 5A) as well as in the cortex where it
was more profound (Figs. 4B and 5B). In the thalamus of the
5XFAD/LDLR-/- mice we also noticed the formation of Iba-1
positive round cell formations surrounding Thioflavine-S positive
amyloid deposits not observed in any other genotype (Fig. 5C).
These results indicate that the LDLR deficiency is affecting the
neuroinflammatory response in the 5XFAD mouse model. Our
results also suggest that this effect is not mediated by ApoE.
Discussion
ApoE is a major risk factor in the pathogenesis of AD in the
human population. The e4 allele of ApoE predisposes to AD while
the e2 allele is protective [29,30]. ApoE2 has been shown to have a
very low binding capacity to the LDLR compared to ApoE3 or
ApoE4 [4]. This difference in the binding ability to LDLR has lead
to the hypothesis that LDLR is a potential mediator of the
differential effect of the ApoE alleles on Ab clearance and
aggregation. Previous studies where the LDLR gene was deleted
or over-expressed in AD transgenic mice indeed confirmed the
role of the LDLR in amyloid deposition [20,25,27]. In all these
studies LDLR was shown to regulate ApoE levels in the brain
suggesting that ApoE is possibly the key mediator of the effect on
amyloid deposition. Nevertheless deletion of LDLR in huAPP
transgenic mice into two separate studies resulted in opposing
evidence on the effect of LDLR deletion in amyloid deposition,
with one study having no effect and the other showing a significant
increase [20,25]. To clarify the role of LDLR deficiency in
amyloid deposition in a huAPP transgenic mouse model we
generated and analyzed a novel huAPP/PS1 transgenic mouse
deficient for LDLR. Also in the present study we examined
whether LDLR effect on amyloid deposition is dependent on
ApoE, or whether LDLR can exert any effect independent of
ApoE on the pathogenesis of the amyloid related phenotype in this
AD mouse model. ApoE has a major impact on the generation of
amyloid deposits in the AD mouse brain and deletion of ApoE in
most AD mouse models significantly inhibits amyloid plaque
formation [6,7,8]. In this study we used an AD mouse model
(5XFAD) that carries both huAPP and huPS1 mutant transgenes
and starts to develop amyloid deposits at the early age of two
months [28]. We backcrossed 5XFAD transgenic mice to the
ApoE deficient background and we found a great reduction in
amyloid load as expected. Although there was a significant
reduction in amyloid deposition, 5XFAD/ApoE-/- mice developed
amyloid plaques in the subiculum at the early age of four months.
Also as it has been reported with other APP/PS1 transgenic mice,
we observed a sex-specific effect on amyloid deposition with
5XFAD female mice developing amyloid deposits earlier com-
pared to male littermates [27,31,32]. As the prevalence of AD is
higher in women it is noteworthy that a similar mechanism is likely
to be present in the mice [33].
Figure 1. LDLR deficiency results in increased Thioflavine-S
plaque load in the presence or in the absence of ApoE. A–B.
Representative pictures of Thioflavine-S staining in cortices (A) and
hippocampi (B) of the analyzed groups (n = 527, 6–7 sections per
animal, 240 mm apart). The absence of LDLR results in increased
Thioflavine-S positive staining in the 5XFAD mice in the presence (A and
B upper photos) or the absence of ApoE (A and B lower photos). Scale
bar 0.5 mm. C. Magnification of the subiculum of the 5XFAD/ApoE-/-
and the 5XFAD/ApoE-/-LDLR-/- mice, showing the difference in
abundance of Thioflavine-S positive plaques. Scale bar 0.1 mm. D.
Quantitation of Thioflavine-S positive staining in the hippocampi (left)
and cortices (right) of female mice showing the increase in the amyloid
plaques in the 5XFAD/LDL-/- and 5XFAD/ApoE-/-LDLR-/- mice. One-way
ANOVA showed a significant difference among groups (P,0.0001)
followed by Student’s t-test. * P,0.05. P-values among groups are
analysed in Table 1.
doi:10.1371/journal.pone.0021880.g001
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To evaluate the effect of LDLR deletion on amyloid deposition
we generated 5XFAD/LDLR-/- mice and compared amyloid
deposition to the 5XFAD mice. We found that LDLR deletion
increases Thioflavine-S positive amyloid deposits both in the
hippocampus and the cortex as it has been previously reported
using a different AD mouse model. [25]. We also found that ApoE
levels are increased in the 5XFAD/LDLR-/- mice compared to
5XFAD mice suggesting that LDLR regulates ApoE levels in the
brain.
Next, to examine whether the increase in amyloid deposition
induced by the LDLR deficiency is mediated exclusively by the
effect of LDLR on ApoE, we generated 5XFAD/ApoE-/-LDLR-/-
mice and compared amyloid deposition to the 5XFAD/ApoE-/-
mice. We found that deletion of LDLR in the 5XFAD/ApoE-/-
LDLR-/- mice increased amyloid deposition in the absence of
ApoE. The pattern of formation of amyloid deposits both in the
5XFAD/ApoE-/- and the 5XFAD/ApoE-/-LDLR-/- mice was
characteristic with absence of deposits in the molecular layer of the
hillus of the hippocampus suggesting that lack of LDLR can
enhance amyloid deposition but cannot modify the pattern of
deposition that is dictated by ApoE. We also found that LDL
deletion or double ApoE LDLR deletion has no impact on the
APP processing and production of a and b-CTFs fragments in the
mouse brain, suggesting that the effect on amyloid deposition
resulted from increased Ab aggregation and reduced clearance.
Our results, using the 5XFAD mouse model, confirm that LDLR
is involved in amyloid deposition as shown in previous studies.
Deletion of LDLR confers a negative effect according to our data
and other studies [20,25] while over-expression diminishes
amyloid deposition [27]. Moreover our data demonstrate that
LDLR deletion has an effect on amyloid deposition independent of
ApoE as 5XFAD/ApoE-/-LDLR-/- mice have increased amyloid
deposition compared to the 5XFAD/ApoE-/- mice. These results
imply that LDLR might be involved in a mechanism affecting
amyloid deposition where ApoE is not involved.
A major characteristic of AD pathology is the increased
inflammatory response that is observed close and around the
amyloid plaques. Many studies have suggested that the brain’s
immune system, microglia and astrocytes play a major role in AD
pathogenesis [34,35]. As 5XFAD transgenic mice display early
astrogliosis and microgliosis associated with amyloid deposits, we
examined the effect of LDLR deficiency on astrogliosis and
microgliosis in the mouse brain. We found that despite the
increase of amyloid deposits in the 5XFAD/LDLR-/- mice there
was a profound decrease both in the astrocytic and microglial
response compared to the 5XFAD mice. The same effect was
observed in the 5XFAD/ApoE-/-LDLR-/- mice compared to the
Table 1. Results of Student’s t-test for Thioflavine-S positive amyloid deposits of the analyzed groups.
Group 1 (hippocampus) Group 2 (hippocampus) P value
5xFAD 5xFAD/LDLR-/- P = 0.03 (*)
5xFAD/ApoE-/- 5xFAD/ApoE-/-LDLR-/- P = 0.0274 (*)
5xFAD 5xFAD/ApoE-/- P = 0.013 (*)
5xFAD 5xFAD/ApoE-/-LDLR-/- P = 0.0139 (*)
5xFAD/LDLR-/- 5xFAD/ApoE-/- P = 0.0003 (***)
5xFAD/LDLR-/- 5xFAD/ApoE-/-LDLR-/- P = 0.0003 (***)
Group 1 (Cortex) Group 2 (Cortex) P value
5xFAD 5xFAD/LDLR-/- P = 0.0452 (*)
doi:10.1371/journal.pone.0021880.t001
Figure 2. Lack of LDLR increases brain ApoE levels in the
5XFAD/LDLR-/- mice and has no effect on the APP processing.
A. Western blot for ApoE of protein extracts of 5XFAD and 5XFAD/
LDLR-/- mouse brains. Tubulin was used as a loading control. 30 mg
from the guanidine fraction of brain homogenates was loaded in each
lane. In the absence of LDLR the levels of brain ApoE are increased. B.
Densitometry of western blots shows a significant increase in the levels
of ApoE in the guanidine fraction of total brain extracts. Statistical
analysis was performed with the Student’s t-test (** P = 0.0041). C. 10 mg
of protein from the lysis fraction of total brain homogenates were
loaded in each lane and immunoblotted for full length APP and CTFs.
GAPDH was used as a loading control. No difference was observed in
the full length APP or the CTFs when normalised to the control
indicating that LDLR deficiency has no effect on the steady-state levels
of full-length APP or on a- and b-secretase activity (5-7 animals per
genotype were analysed and the experiments were repeated 3 times).
doi:10.1371/journal.pone.0021880.g002
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5XFAD/ApoE-/- mice. This was very obvious in the subiculum
and in the cortex where amyloid plaques were formed. This was
not expected as microglial and astrocytic response is proportional
to the amyloid deposition and was expected to be more than less
compared to the controls. These data clearly suggest for the
possible involvement of LDLR in the glial response in the AD
mouse brain. Also this effect is not related to ApoE as it is observed
both in the 5XFAD/LDL-/- and the 5XFAD/ApoE-/-LDLR-/-
mice. An effect in the glial response related to LDLR has been also
reported in another study where an LDLR transgene has been
expressed in the brain of another AD mouse model [27]. In this
study LDLR over-expression resulted in reduced amyloid
deposition with decreased glial response. Glial response has been
shown to be proportional to the amyloid deposition in most
transgenic mice therefore a reduction in astrocytic and microglial
response is an expected effect following reduced amyloid
deposition.
Our study suggests that LDLR is not only able to regulate ApoE
levels in the brain thus affecting amyloid deposition, but it can
have an effect on amyloid deposition independent of ApoE by
regulating glial response. Our data along with previous studies
show that LDLR has an effect on amyloid deposition as other
members of the LDLR family of receptors. LRP1 has also been
shown to be involved in the clearance of amyloid [36,37,38]. It is
likely that the LDLR acts jointly with the LRP1 and the deletion of
LDLR is partially compensated by LRP1 in the clearance of Ab.
In this study we also showed that LDLR is able to regulate the
glial response, both astrocytic and microglial in the absence of
ApoE. The increased formation of amyloid deposits in the
5XFAD/ApoE-/-LDLR-/- mice can be attributed to down-regu-
lation of the glial inflammatory response. A defective cholesterol
homeostasis can be a possible explanation for this effect. Abnormal
cholesterol homeostasis caused by deletion of ApoE or other
Figure 3. LDLR deletion increases Ab deposition in the mouse
hippocampus. A. Immunohistochemistry for total Ab (6E10) in the
brains of female mice. Representative pictures are shown for each
genotype. The Ab deposition is increased in the subiculum of the
5XFAD/LDLR-/- mice compared to the 5XFAD mice. The same effect is
observed in the 5XFAD/ApoE-/-LDLR-/- mice where Ab deposition is
more intense in the subiculum. Ab deposition in the 5XFAD/ApoE-/-
LDLR-/- cortices appears more ‘dense’ and ‘‘compact’’ compared to the
5XFAD/ApoE-/- mice where Ab deposition is more ‘‘diffuse’’. Scale bar
0.5 mm (n = 527, 6–7 sections per animal, 240 mm apart). B.
Quantitation of Ab immunoreactivity in the hippocampi (left) of the
analysed groups shows a significant increase in the Ab deposition in the
5XFAD/LDLR-/- and the 5XFAD/ApoE-/-LDLR-/- mice. In the cortices
(right) there is no significant difference between 5XFAD and 5XFAD/
LDLR-/- as well as between 5XFAD/ApoE-/- and 5XFAD/ApoE-/-/LDLR-/-.
*P,0.05. P-values among all groups are analysed in Table 2 and Table 3
for hippocampi and cortices respectively. C. Quantitation of Ab42 and
Ab40 levels by ELISA in the 5XFAD and the 5XFAD/LDLR-/- mouse brain
extracts showed an increase both in the guanidine and lysis fraction in
the 5XFAD/LDLR-/- mice. A similar increase was also observed in the
guanidine fraction of the 5XFAD/ApoE-/-LDLR-/- mice compared to the
5XFAD/ApoE-/- but not in the lysis fraction (n = 527) *P,0.05,
**P,0.001.
doi:10.1371/journal.pone.0021880.g003
Table 2. Results of Student’s t-test for Ab immunostaining in
the hippocampi of the analyzed groups.
Group 1 Group 2 P value
5XFAD 5XFAD/LDLR-/- P = 0.0281 (*)
5XFAD/ApoE-/- 5XFAD/ApoE-/-LDLR-/- P = 0.0493 (*)
5XFAD 5XFAD/ApoE-/- P = 0.0059 (**)
5XFAD 5XFAD/ApoE-/-LDLR-/- P = 0.0001 (***)
5XFAD/LDLR-/- 5XFAD/ApoE-/- P = 0.0215 (*)
5XFAD/LDLR-/- 5XFAD/ApoE-/-LDLR-/- P,0.0001 (***)
doi:10.1371/journal.pone.0021880.t002
Table 3. Results of Student’s t-test for Ab immunostaining in
the cortices of the analyzed groups.
Group 1 Group 2 P value
5XFAD 5XFAD/LDLR-/- P = 0.0546 (ns)
5XFAD/ApoE-/- 5XFAD/ApoE-/-LDLR-/- P = 0.3385 (ns)
5XFAD 5XFAD/ApoE-/- P = 0.007 (**)
5XFAD 5XFAD/ApoE-/-LDLR-/- P = 0.0297 (*)
5XFAD/LDLR-/- 5XFAD/ApoE-/- P = 0.0179 (*)
5XFAD/LDLR-/- 5XFAD/ApoE-/-LDLR-/- P = 0.006 (**)
doi:10.1371/journal.pone.0021880.t003
Increase of Ab Deposition by LDLR Deletion
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Figure 4. Astrocytosis is decreased in the brains of 5XFAD/LDLR-/- and 5XFAD/ApoE-/- LDLR-/- mice. Immunohistochemistry for GFAP
(red) and Thioflavine-S (green) in the hippocampi (A) and the cortices (B) of mouse brains. Representative pictures are shown for each genotype. In
both areas examined the absence of LDLR results in reduction of GFAP immunoreactivity. Astrocytosis in both the cortex and the hippocampus is
Increase of Ab Deposition by LDLR Deletion
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cholesterol receptors as the SR-BI has been shown to cause altered
responses to different immune cell types like the macrophages
[39], although LDLR has not been implicated in regulating
immune responses in the brain or the periphery so far.
The present study further implicates LDLR in the pathogenesis
of AD suggesting LDLR as a potential regulator of the glial
response in the development of the AD-like phenotype in an AD
mouse model. Moreover we show that this effect can be inde-
pendent of ApoE suggesting a novel mechanism.
In conclusion, our results provide new evidence regarding the
role of LDLR in the pathogenesis of Alzheimer’s disease suggesting
that LDLR could be a potential therapeutical target in AD.
Materials and Methods
Animals
LDLR-/-, ApoE-/- and 5XFAD transgenic mice were obtained
from The Jackson Laboratory, Bar Harbor, ME. ApoE-/- and
5XFAD mice were on the C57Bl6/J background. LDLR-/- were
on C57Bl6/J;129S2 mixed genetic background and have been
backcrossed for at least six generations to C57Bl6/J background.
All test and control mouse groups analyzed for Ab related
pathology were 4 months old. Only female mice were analyzed as
female 5XFAD transgenic mice develop the amyloid related
phenotype earlier compared to males of the same age. To generate
5XFAD/LDLR-/- mice, 5XFAD mice were mated with LDLR-/-
mice and the resulting 5XFAD/LDLR+/- mice were mated with
the LDLR-/- mice. 5XFAD/LDLR-/- were identified by PCR.
The same strategy was used to generate 5XFAD/ApoE-/- mice.
5XFAD mice were mated with ApoE-/- mice and the resulting
5XFAD/ApoE+/- mice were mated with the ApoE-/- mice.
5XFAD/ApoE-/- mice were identified by PCR. To generate
ApoE-/-LDLR-/- mice, ApoE-/- mice were mated to LDLR-/-
mice. The ApoE+/-LDLR+/- that resulted from this cross were
mated with each other and ApoE-/-LDLR-/- mice were identified
by PCR. To generate 5XFAD/ApoE-/-LDLR-/- mice 5XFAD
mice were mated with ApoE-/-LDLR-/- mice and the resulting
5XFAD/ApoE+/-LDLR+/- mice were mated with the ApoE-/-
LDLR-/- mice. 5XFAD/ApoE-/-LDLR-/- mice were identified by
PCR. All mice were maintained on a standard chow diet
containing 5% fat. All animal procedures were approved by the
Bioethical committee of the Biomedical Research Institute of the
Academy of Athens and by the Prefecture of Athens, Greece. All
animal experimentations were carried out in agreement with
ethical recommendation of the European Communities Council
Directive of 24 November 1986 (86/609/EEC). Standard PCR
techniques were used to genotype the 5XFAD, ApoE and LDLR
genotypes.
Tissue collection
Mice were anesthetized and transcardially perfused with PBS
0.1 M pH 7.4. Tissues were harvested immediately after perfu-
sion. Left hemibrains were snap-frozen in liquid nitrogen for
protein analysis. Right hemibrains were immersion-fixed in 4%
PFA in PBS for 48 hours and cryoprotected in 20% sucrose in
PBS for immunohistochemistry.
Protein extraction from brain tissue
Protein extraction from left hemibrains was performed in three
consecutive steps in order to evaluate protein levels in PBS, Lysis
buffer (containing 10% glycerol, 1% Triton X-100 and complete
protease inhibitor (Roche Applied Science) in PBS) and Guanidine
fractions (5 M Guanidine-HCl) respectively as described before
[21]. Brain tissue from all animals was extracted in an identical
manner, and all fractions were immediately frozen at -80uC until
analysis. Protein concentrations were determined by BCA Protein
Assay (Pierce).
Western blot
Left hemibrains tissues were homogenised as designated above
and 30 mg of total protein were separated in a 10% SDS-PAGE
Tris-Glycine for ApoE and Tubulin. In brief, after electrophoresis,
proteins were transferred to a PVDF membrane (Immobilon-P,
Millipore), blocked for 1 hour at room temperature with 5% milk
in TBS-Tween 0.05% (TBST) and incubated for 1 hour at room
temperature with goat anti-ApoE (M20, 1:2000, Santa Cruz) or
mouse anti-Tubulin (3D10, 1:500, Sigma) in blocking solution.
After washes with TBST blots were incubated with appropriate
secondary antibodies (Santa Cruz) for 1 hour. For APP western
blot 10 mg of total protein were separated in a 12% Tris-Tricine
gel and transferred to nitrocellulose membrane (Protran, What-
man). Membranes were blocked for 30 minutes at 37uC in 5%
FCS and incubated overnight at 4uC with rabbit polyclonal anti-
human APP 1:2500 [R1(57), a kind gift by Dr. P. Mehta, Institute
for basic research in developmental disabilities, Staten Island, NY]
[40]. The following day the membrane was washed 3 times with
TBST and incubated for 1 hour at room temperature with goat-
anti-rabbit HRP-conjugated (Santa Cruz). Blots were developed
using ECL (Amersham) according to the manufacturer’s recom-
mendations. Bands were quantitated by densitometry using NIH
Image J software.
Immunohistochemistry
Brains were fixed in 4% PFA in PBS for 48 hrs and then were
cryoprotected in 20% sucrose in PBS (0.1 M PBS, pH 7.4). Fixed
hemibrains were cut in 40-mm sagittal floating sections from the
genu of the corpus callosum to the most caudal hippocampus using
a vibratome (Leica VT1000S). For total Ab immunostaining 6–7
sagittal sections 240 mm apart from each other spanning all the
hippocampal formation were chosen. Sections were washed with
TBS-0.1% Triton X-100 3 times for 10 minutes each, incubated
for 30 min with 0.3% H2O2 in TBS and washed with TBS 3
times. Antigen retrieval was performed with 98% formic acid for
5 min, followed by 3 washes with TBS. Sections were transferred
into blocking solution containing 15% normal donkey serum
(Vector Laboratories) in TBS-Triton X-100 0.1% for 1 hour and
incubated overnight at 4uC in 5% normal donkey serum (Vector
Laboratories) in TBS-Triton X-100 0.1% containing the mono-
clonal biotinylated 6E10 primary antibody (1:1000, Signet).
Sections were then washed five times with TBS-Triton X-100
0.1%, and incubation in avidin-biotinylated horseradish peroxi-
dase complex (ABC Elite, Vector Laboratories) followed for
90 min at room temperature. Peroxidase labelling was visualized
more intense in the 5XFAD and the 5XFAD/ApoE-/- compared to the 5XFAD/LDLR-/- and the 5XFAD/ApoE-/-LDLR-/- sections respectively. Scale bar
250 mm. The pictures were taken under the same conditions of intensity and the experiment was repeated 3 times. (n = 527, 324 independent
sections per animal were analyzed). C. Quantitation of GFAP positive staining in the hippocampi and cortices showing a decrease in the 5XFAD/LDL-/-
and 5XFAD/ApoE-/-LDLR-/- mice compared to the control mice. P-values in the hippocampi (left graph) ** P = 0.0040 for 5XFAD vs. 5XFAD/LDLR-/- and
P= 0.0031 for 5XFAD/ApoE-/- vs. 5XFAD/ApoE-/-LDLR-/-. In the cortices (right graph) * P = 0.0399 for 5XFAD vs. 5XFAD/LDLR-/- and P= 0.0205 for
5XFAD/ApoE-/- vs. 5XFAD/ApoE-/-LDLR-/-.
doi:10.1371/journal.pone.0021880.g004
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with DAB/Ni (Vector). After a 1-min incubation period, sections
were washed, mounted on glass slides, dehydrated in increasing
ethanol concentrations from 50 to 100% followed by xylene and
coverslipped with DPX (BDH).
The specificity of immunoreactivity was confirmed both by
omitting the primary antibody and by the lack of signal when
applying the same protocol on brain sections of wild-type littermates.
Immunofluorescence
For the estimation of amyloid plaque load in transgenic mice, 6–
7 sagittal sections 240 mm apart from each other spanning all the
hippocampal formation were chosen for Thioflavine-S staining.
Sections were incubated for 8 minutes in aqueous solution of
Thioflavine-S (1% w/v) and then differentiated 2 times with 80%
Ethanol for 3 minutes each, followed by another 3-minutes wash
with 95% Ethanol. Sections were rinsed three times with ddH2O
and coverslipped with Vectashield fluorescence mounting medium
(Vector). Imaging for Thioflavine-S was performed on a Leica
DMRA 2 microscope (magnification 2.5x for cortices and 5x for
hippocampi) and image captivation was performed using Leica
Application Suite, version 2.8.1 software. For the analysis of the
inflammatory response in the brains of mice, the GFAP and Iba1
markers for astrocytes and microglia respectively were used. For
GFAP and Thioflavine-S, free-floating sections were washed 3
times with 16TBS pH 7.6, blocked with 16TBS-Triton X-100
0.4%, 5% Normal Goat Serum (Vector) for 1 hour at room
temperature and incubated overnight at 4uC with rabbit
polyclonal anti-GFAP (1:1000, Sigma). The following day, sections
were washed five times with 16TBS and incubated in blocking
solution with goat anti-rabbit Cy3-conjugated (1:300, Jackson
ImmunoResearch) for 1 hour at room temperature. Sections were
washed with 16TBS and immersed in Thioflavine-S (1% w/v
aqueous solution) for 5 minutes. Sections were differentiated twice
with 70% Ethanol and rinsed 3 times with PBS (0,1 M pH 7.4).
Sections were mounted on glass slides and coversliped with
Vectashield fluorescence mounting medium (Vector). For Iba1
and Thioflavine-S immunofluorescence sections were permeabi-
lized for 30 minutes with PBS-Triton X-100 0.1% at room
temperature, blocked for 3 hours with 10% fetal calf serum (FCS),
1% BSA (fraction V, Sigma) in PBS-Triton X-100 0.1% and
incubated overnight at 4uC with rabbit anti-Iba1 (1:300, Wako) in
1% FCS, 0.1% BSA, PBS-Triton X-100 0.01%. The following
day, sections were washed 5 times with PBS and incubated with
goat anti-rabbit Cy3-conjugated (1:300, Jackson Immunoresearch)
for 1 hour at room temperature. Sections were washed 5 times
with 16TBS and stained for Thioflavine-S as described above.
Imaging was performed with a Leica TCS SP5 Confocal micro-
scope and pictures were captured and analyzed with the Leica
LAS AF Suite.
Quantitation and statistical analysis
Images were analysed with the NIH Image J software. For the
Ab or Thioflavine-S load the images were thresholded within a
linear range and the load was defined as the per cent area covered
by Ab or Thioflavin-S positive plaques (% Ab or Thioflavin-S
load). For Iba1 and GFAP the mean intensity of the immunoflu-
orescent signal within a linear range was analysed. All data are
expressed as mean6SEM. Statistical significance of differences
was evaluated either with Student’s t-test or with one way
ANOVA followed by the two-way Student’s t-test. In the t-test
analyses, Welch’s correction for unequal variances was applied
when variances were significantly different between groups.
Probability values P,0.05 were considered significant. All statis-
tical analyses were performed using GraphPad Prism (version 4.0;
Graphpad software for Science Inc., San Diego).
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